Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action
Open Access
- 1 June 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 101 (4) , 638-646
- https://doi.org/10.1046/j.1365-2141.1998.00770.x
Abstract
Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)‐induced blood coagulation, which is increased several‐fold in post‐heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. In the present study we investigated whether subcutaneous (s.c.) administration of a low molecular weight heparin (LMWH), enoxaparin, had a different effect on intravascular pools of TFPI compared with continuous i.v. infusion of unfractionated heparin (UFH). 18 healthy male volunteers were randomly assigned to continuous i.v. infusion with UFH (initially 450 U/kg/24 h, n = 6) or to s.c. treatment with LMWH once daily (enoxaparin, 1.5 mg/kg, n = 12) for 72 h. A bolus injection of 5000 IU UFH i.v. caused an 8–13‐fold increase in plasma‐free TFPI antigen (TFPI Ag), followed by a progressive decrease (81 ± 4%, P < 0.001) during the 72 h infusion with UFH. 4 h after discontinuation of the infusion, basal free TFPI Ag and heparin‐releasable TFPI were significantly decreased compared with the concentrations before the infusion (30 ± 9% and 27 ± 7%, respectively). In contrast, LMWH treatment did not reduce either basal or heparin‐releasable TFPI Ag. The changes in plasma TFPI Ag by UFH and LMWH were statistically different between groups both in pre‐ (P < 0.001) and post‐heparin (P < 0.0001) plasma. The differential effect of UFH and LMWH on intravascular pools of TFPI may contribute to the understanding of the apparent superior efficacy of LMWHs in the treatment of both arterial and venous thrombosis.Keywords
This publication has 38 references indexed in Scilit:
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemiaJournal of the American College of Cardiology, 1995
- Blocking of tissue factor pathway inhibitor (TFPl) shortens the bleeding time in rabbits with antibody induced haemophilia ABlood Coagulation & Fibrinolysis, 1995
- Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin in Patients With Acute Coronary SyndromesCirculation, 1995
- Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitorThrombosis Research, 1993
- Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.Proceedings of the National Academy of Sciences, 1990
- Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitorNature, 1989
- Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administrationThrombosis Research, 1985